Skip to main content
Premium Trial:

Request an Annual Quote

Claude Benchimol, John Carrino, Catherine Burzik, Andrew Creasey, David Danley


Claude Benchimol has been appointed senior vice president of R&D, and John Carrino has been appointed chief scientist at Invitrogen. Benchimol was most recently vice president and general manager of global technology for General Electric’s Medical Systems IT division. He worked at GE in various leadership roles for a total of 15 years. Benchimol holds a master’s degree in engineering from École Nationale Superièure des Télécommunications in Paris, as well as a master’s and PhD in system science from the University of California Los Angeles. Carrino was previ-ously vice president of R&D for Invitrogen. He has also worked in R&D at Nanogen and Abbott Laboratories, and holds a PhD in microbiology and immunology from Northwestern University.

Catherine Burzik has been appointed executive vice president of Applied Biosystems. She was previously president of Ortho-Clinical Diagnostics, a subsidiary of Johnson & Johnson. Before that, she was general manager and vice president of Critikon, another Johnson & Johnson company.

Andrew Creasey has become president of NextGen Sciences Inc., the newly-formed Bedford, Mass.-based US subsidiary of Huntingdon, UK-based NextGen Sciences Ltd. Creasey was most recently director of marketing at Harvard Biosciences. Creasey holds a PhD in molecular genetics from the University of Newcastle-upon-Tyne, UK.

David Danley has been appointed director of homeland security and defense programs at CombiMatrix. Danley is a retired colonel for the US Army and was previously project manager of the Chemical Biological Medical Systems and Joint Vaccine Acquisition Program for the Department of Defense. Danley holds a BS in biology from Portland State University and a PhD in biological sciences from Purdue University.


The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.